Soleno Therapeutics Inc (SLNO) - Total Assets
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) holds total assets worth $608.39 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Soleno Therapeutics Inc - Total Assets Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see SLNO market cap for the company's overall valuation and market capitalisation.
Soleno Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Soleno Therapeutics Inc's total assets of $608.39 Million consist of 63.1% current assets and 36.9% non-current assets. Review SLNO liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.4% |
| Accounts Receivable | $28.21 Million | 5.0% |
| Inventory | $15.02 Million | 2.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.86 Million | 0.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Soleno Therapeutics Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Soleno Therapeutics Inc's current assets represent 63.1% of total assets in 2025, a decrease from 95.0% in 2012.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, down from 85.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 5.0% of total assets.
Soleno Therapeutics Inc Competitors by Total Assets
Key competitors of Soleno Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
|
China | CN¥4.08 Billion |
Soleno Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.62 | 19.64 | 4.13 |
| Quick Ratio | 5.32 | 19.64 | 4.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $268.33 Million | $293.18 Million | $26.18 Million |
Soleno Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Soleno Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.13 |
| Latest Market Cap to Assets Ratio | 4.89 |
| Asset Growth Rate (YoY) | 70.4% |
| Total Assets | $563.83 Million |
| Market Capitalization | $2.76 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Soleno Therapeutics Inc's assets at a significant premium (4.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Soleno Therapeutics Inc's assets grew by 70.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual total assets of Soleno Therapeutics Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $563.83 Million | +70.36% |
| 2024-12-31 | $330.97 Million | +83.17% |
| 2023-12-31 | $180.69 Million | +581.93% |
| 2022-12-31 | $26.50 Million | -25.47% |
| 2021-12-31 | $35.55 Million | -45.29% |
| 2020-12-31 | $64.98 Million | +70.23% |
| 2019-12-31 | $38.17 Million | -11.54% |
| 2018-12-31 | $43.15 Million | +10.58% |
| 2017-12-31 | $39.02 Million | +601.22% |
| 2016-12-31 | $5.56 Million | -32.15% |
| 2015-12-31 | $8.20 Million | -2.32% |
| 2014-12-31 | $8.40 Million | +429.15% |
| 2013-12-31 | $1.59 Million | -36.89% |
| 2012-12-31 | $2.51 Million | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more